Home > Press > Microfluidics announces retirement of Robert Bruno
Abstract:
Microfluidics, a wholly owned subsidiary of MFIC Corporation, has announced that Robert Bruno will retire from his position as President and Chief Operating Officer effective, June 30, 2008.
Mr. Bruno, a licensed Professional Engineer and a graduate of Northeastern University with an advanced degree in Mechanical Engineering, joined Microfluidics in March of 1996 as Vice President of Sales and Marketing. He was promoted to President and Chief Operating Officer of both Microfluidics and MFIC in March 2001.
Over the last twelve years, Mr. Bruno worked to grow the Company's business through product innovation, the expansion of a global sales network and the establishment of highly effective engineering and manufacturing organizations. Mr. Bruno spearheaded the development of the Company's Microfluidizer® processor model M-700 standardized "BioPharm" product line, which played a critical role in Microfluidics' rapid growth in the biopharmaceutical markets.
More recently, Mr. Bruno led the design and development of Microfluidics' highly successful new product, the M-110P laboratory Microfluidizer processor. During his tenure, Mr. Bruno also oversaw the introduction of several key differentiating product features that established Microfluidics as a world leader in biopharmaceutical high shear fluid processing.
"It has been a pleasure working with Bob as he has made significant contributions to the development of our business, our product portfolio and the overall organization," stated Michael C. Ferrara, Chief Executive Officer of MFIC. "We appreciate his dedication over the years and wish him all the best in his retirement."
"I'm proud to have played a role in the growth of Microfluidics and to have been associated with such a great team of dedicated employees," said Mr. Bruno. "While I am happy to be retiring, I am highly confident in the future of Microfluidics and look forward to monitoring its continued success."
####
About Microfluidics
Microfluidics, a wholly owned subsidiary of MFIC Corporation, is a supplier of advanced fluid processing equipment and reaction technology for laboratory, pilot scale and manufacturing applications. The equipment enables the manufacture and formulation of numerous nanomaterials and nanoscale products and produces the most uniform and smallest liquid and suspended solid particles available.
Microfluidics has been a worldwide supplier of Microfluidizer® high shear fluid processing systems to the biotechnology, pharmaceutical, chemical, cosmetics/personal care and food industries since 1984. As leader in the field, Microfluidics has enabled numerous companies and institutions to formulate, validate and produce licensed drugs for the worldwide healthcare market.
Companies seeking to produce difficult-to-formulate products or to find better methods of bio-processing can take advantage of complimentary sample testing at one of three Microfluidics facilities. Visit www.microfluidicscorp.com, email or contact Microfluidics at 800.370.5452 for application information.
For more information, please click here
Contacts:
Katie DePorter
Gray & Rice Public Relations
617-367-0100 ext. 121
Copyright © Microfluidics
If you have a comment, please Contact us.Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Related News Press |
News and information
Beyond wires: Bubble technology powers next-generation electronics:New laser-based bubble printing technique creates ultra-flexible liquid metal circuits November 8th, 2024
Nanoparticle bursts over the Amazon rainforest: Rainfall induces bursts of natural nanoparticles that can form clouds and further precipitation over the Amazon rainforest November 8th, 2024
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Microfluidics/Nanofluidics
Implantable device shrinks pancreatic tumors: Taming pancreatic cancer with intratumoral immunotherapy April 14th, 2023
Researchers design new inks for 3D-printable wearable bioelectronics: Potential uses include printing electronic tattoos for medical tracking applications August 19th, 2022
Oregon State University research pushes closer to new therapy for pancreatic cancer May 6th, 2022
Announcements
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Turning up the signal November 8th, 2024
Nanofibrous metal oxide semiconductor for sensory face November 8th, 2024
The latest news from around the world, FREE | ||
Premium Products | ||
Only the news you want to read!
Learn More |
||
Full-service, expert consulting
Learn More |
||